88%Confidence
0Views
FDASource
2026-04-05Date
Summary
Harbin Jixianglong's Semaglutide recall due to incomplete validation processes reveals significant regulatory compliance failures in the high-demand weight loss drug compounding market. This creates opportunities for compliant competitors while highlighting risks in the compounding pharmacy supply chain.
Actionable: Immediately discontinue use of Semaglutide from this manufacturer and source from FDA-approved suppliers with validated processes.
AI Confidence: 88%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now